3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma Of Esophagus
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Lung Diseases
1
Kidney Neoplasms
1
Esophageal Neoplasms
1
Erythrocytosis, Familial, 4
1
Cholangiocarcinoma
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
cabozantinib
4
Nivolumab
2
Ipilimumab
2
zimberelimab
1
temsirolimus
1
salicylhydroxamic acid
1
orellanine
1
atezolizumab
1
Surveys and Questionnaires
1
Ropivacaine
1
Pluvicto
1
Methods
1
Health Promotion
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Genetic Counseling
1
Erlotinib Hydrochloride
1
Educational Status
1
Early Intervention, Educational
1
Docetaxel
1
Dacarbazine
1
Counseling
1
Blood Component Removal
1
Axitinib
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
zimberelimab
×
30 days
×
Clear all
NCT05536141
2026-06-01
ARC-20
Arcus Biosciences, Inc.
Phase 1
Recruiting
362 enrolled